HUE057087T2 - TIGIT-hez kötõdõ ágensek és alkalmazásaik - Google Patents

TIGIT-hez kötõdõ ágensek és alkalmazásaik

Info

Publication number
HUE057087T2
HUE057087T2 HUE16800775A HUE16800775A HUE057087T2 HU E057087 T2 HUE057087 T2 HU E057087T2 HU E16800775 A HUE16800775 A HU E16800775A HU E16800775 A HUE16800775 A HU E16800775A HU E057087 T2 HUE057087 T2 HU E057087T2
Authority
HU
Hungary
Prior art keywords
tigit
binding agents
binding
agents
Prior art date
Application number
HUE16800775A
Other languages
English (en)
Inventor
Austin Gurney
Ming-Hong Xie
Original Assignee
Mereo Biopharma 5 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mereo Biopharma 5 Inc filed Critical Mereo Biopharma 5 Inc
Publication of HUE057087T2 publication Critical patent/HUE057087T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HUE16800775A 2015-05-28 2016-05-27 TIGIT-hez kötõdõ ágensek és alkalmazásaik HUE057087T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562167582P 2015-05-28 2015-05-28
US201562205279P 2015-08-14 2015-08-14
US201662313487P 2016-03-25 2016-03-25

Publications (1)

Publication Number Publication Date
HUE057087T2 true HUE057087T2 (hu) 2022-04-28

Family

ID=57393726

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16800775A HUE057087T2 (hu) 2015-05-28 2016-05-27 TIGIT-hez kötõdõ ágensek és alkalmazásaik

Country Status (29)

Country Link
US (2) US10112997B2 (hu)
EP (2) EP3303379B1 (hu)
JP (2) JP6875295B2 (hu)
KR (1) KR20180014050A (hu)
CN (2) CN115429877A (hu)
AU (1) AU2016267577B2 (hu)
BR (1) BR112017025529A2 (hu)
CA (1) CA2987607A1 (hu)
CL (1) CL2017003021A1 (hu)
CO (1) CO2017012342A2 (hu)
CY (1) CY1125260T1 (hu)
DK (1) DK3303379T3 (hu)
EC (1) ECSP17083779A (hu)
ES (1) ES2902150T3 (hu)
HR (1) HRP20211948T1 (hu)
HU (1) HUE057087T2 (hu)
IL (1) IL255577B (hu)
LT (1) LT3303379T (hu)
MA (1) MA42622B1 (hu)
MD (1) MD3303379T2 (hu)
MX (1) MX2017014955A (hu)
NZ (1) NZ738008A (hu)
PL (1) PL3303379T3 (hu)
PT (1) PT3303379T (hu)
RS (1) RS62815B1 (hu)
SA (1) SA517390370B1 (hu)
SI (1) SI3303379T1 (hu)
TW (1) TWI715587B (hu)
WO (1) WO2016191643A2 (hu)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090258013A1 (en) 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CR20170060A (es) 2014-08-19 2017-04-18 Merck Sharp & Dohme Anticuerpos anti tigit
CA2971732A1 (en) 2014-12-23 2016-06-30 Bristol-Myers Squibb Company Antibodies to tigit
WO2016134335A2 (en) 2015-02-19 2016-08-25 Compugen Ltd. Pvrig polypeptides and methods of treatment
WO2016134333A1 (en) 2015-02-19 2016-08-25 Compugen Ltd. Anti-pvrig antibodies and methods of use
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
CN108137691B (zh) 2015-09-02 2021-10-19 耶路撒冷希伯来大学伊萨姆研究发展有限公司 特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体
AR109625A1 (es) 2015-10-01 2019-01-09 Potenza Therapeutics Inc Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas
MY191649A (en) 2016-03-04 2022-07-05 Jn Biosciences Llc Antibodies to tigit
WO2017165681A1 (en) 2016-03-24 2017-09-28 Gensun Biopharma Inc. Trispecific inhibitors for cancer treatment
IL310729A (en) 2016-04-15 2024-04-01 Alpine Immune Sciences Inc Immunomodulatory proteins that are variants of CD80 and their uses
MX2018014387A (es) 2016-05-27 2019-03-14 Agenus Inc Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
BR112019002529A2 (pt) 2016-08-09 2019-05-28 Kymab Ltd anticorpo isolado, composição, método para modular o equilíbrio de células t, método para tratar uma doença ou afecção tratável com terapia, método para tratar câncer, combinação de anticorpo igg1, anticorpo anti-icos, mamífero não humano transgênico, e método para produzir um anticorpo
IL301682A (en) 2016-08-17 2023-05-01 Compugen Ltd Antibodies against TIGIT, antibodies against PVRIG and their combinations
US10844119B2 (en) 2016-10-11 2020-11-24 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018102536A1 (en) 2016-11-30 2018-06-07 Oncomed Pharmaceuticals, Inc. Methods for treatment of cancer comprising tigit-binding agents
US10759855B2 (en) 2016-12-02 2020-09-01 Rigel Pharmaceuticals, Inc. Antigen binding molecules to TIGIT
CN109071656B (zh) * 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
JP7118072B2 (ja) * 2017-01-06 2022-08-15 イミュニティーバイオ インコーポレイテッド Ｃｄ９６／ｔｉｇｉｔ発現が低下した遺伝子改変型ｎｋ－９２細胞
KR20190123749A (ko) * 2017-02-28 2019-11-01 시애틀 지네틱스, 인크. 항-tigit 항체
WO2018170023A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
JP7386083B2 (ja) 2017-03-16 2023-11-24 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８０バリアント免疫調節タンパク質及びその使用
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
US20200024351A1 (en) 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
EP3615070A1 (en) 2017-04-26 2020-03-04 Bristol-Myers Squibb Company Methods of antibody production that minimize disulfide bond reduction
TW202402800A (zh) * 2017-05-01 2024-01-16 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體類和使用彼等之方法
SG10202111336RA (en) 2017-06-01 2021-11-29 Compugen Ltd Triple combination antibody therapies
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
KR20200028447A (ko) 2017-07-17 2020-03-16 얀센 바이오테크 인코포레이티드 피브로넥틴 iii형 도메인에 대한 항원 결합 영역 및 이의 사용 방법
BE1025333B1 (fr) * 2017-07-27 2019-01-23 Iteos Therapeutics S.A. Anticorps anti-tigit
AU2018306463A1 (en) * 2017-07-27 2020-03-05 iTeos Belgium SA Anti-TIGIT antibodies
WO2019023504A1 (en) 2017-07-27 2019-01-31 Iteos Therapeutics Sa ANTI-TIGIT ANTIBODIES
WO2019062832A1 (zh) * 2017-09-29 2019-04-04 江苏恒瑞医药股份有限公司 Tigit抗体、其抗原结合片段及医药用途
KR20200074137A (ko) 2017-10-10 2020-06-24 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
CA3078517A1 (en) 2017-10-18 2019-04-25 Alpine Immune Sciences, Inc. Variant icos ligand immunomodulatory proteins and related compositions and methods
EP3697435A1 (en) * 2017-10-20 2020-08-26 Fred Hutchinson Cancer Research Center Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
TW201932489A (zh) * 2018-01-15 2019-08-16 大陸商南京傳奇生物科技有限公司 針對ｔｉｇｉｔ之抗體及其變異體
WO2019204665A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
CN112105645A (zh) 2018-04-18 2020-12-18 Xencor股份有限公司 Il-15/il-15ra异二聚体fc融合蛋白及其用途
AU2019293047A1 (en) 2018-06-29 2021-01-28 Gensun Biopharma Inc. Antitumor immune checkpoint regulator antagonists
WO2020020281A1 (zh) * 2018-07-25 2020-01-30 信达生物制药(苏州)有限公司 抗tigit抗体及其用途
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
JP2022503959A (ja) 2018-10-03 2022-01-12 ゼンコア インコーポレイテッド Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
AU2019359475A1 (en) 2018-10-12 2021-05-20 Xencor, Inc. PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof
US11618776B2 (en) 2018-12-20 2023-04-04 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
CA3123338A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
WO2020144178A1 (en) 2019-01-07 2020-07-16 Iteos Therapeutics Sa Anti-tigit antibodies
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
WO2020176700A1 (en) * 2019-02-27 2020-09-03 Yale University Compositions and methods for enhancing mucosal immunity
EP3938396A1 (en) 2019-03-11 2022-01-19 Jounce Therapeutics, Inc. Anti-icos antibodies for the treatment of cancer
CN109734806B (zh) * 2019-03-15 2022-07-01 安徽安科生物工程（集团）股份有限公司 一种全人源抗huTIGIT单克隆抗体及其应用
TWI760751B (zh) 2019-05-29 2022-04-11 美商美國禮來大藥廠 Tigit及pd-1/tigit-結合分子
BR112021022171A2 (pt) * 2019-06-13 2021-12-21 Green Cross Corp Anticorpo para tigit, seu uso e método para produzir o mesmo
WO2020257760A1 (en) * 2019-06-21 2020-12-24 Single Cell Technology, Inc. Anti-tigit antibodies
CN114007646B (zh) * 2019-06-25 2024-05-10 南京金斯瑞生物科技有限公司 抗cd47/抗tigit双特异抗体及其制备方法和应用
JP2022540571A (ja) 2019-06-28 2022-09-16 ゲンスン バイオファーマ、インコーポレーテッド 変異したＴＧＦβ１－ＲＩＩ細胞外ドメインおよび免疫グロブリン足場で構成される抗腫瘍アンタゴニスト
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CN110669139A (zh) * 2019-09-18 2020-01-10 沣潮医药科技（上海）有限公司 二聚体免疫粘附素、药物组合物和用途
EP3798235A1 (en) * 2019-09-24 2021-03-31 Industrial Technology Research Institute Anti-tigit antibodies and methods of use
WO2021062332A1 (en) * 2019-09-27 2021-04-01 Icahn School Of Medicine At Mount Sinai Combination of inhibitors of il4 signaling and immune checkpoints for treating cancer
EP4037700A2 (en) 2019-10-03 2022-08-10 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
WO2021091960A1 (en) 2019-11-05 2021-05-14 Jounce Therapeutics, Inc. Methods of treating cancer with anti-pd-1 antibodies
CN111018999B (zh) * 2019-12-05 2022-07-12 沣潮医药科技（上海）有限公司 二聚体免疫融合蛋白、药物组合物和用途
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ｏｓｅ免疫治療公司 包含il-7變體之雙官能分子
CN112409450B (zh) * 2020-03-29 2023-01-24 郑州大学 TIGIT-IgV的亲和剂及其应用
CN113563470B (zh) 2020-04-29 2023-02-10 广州昂科免疫生物技术有限公司 结合tigit抗原的抗体及其制备方法与应用
CA3176497A1 (en) 2020-05-07 2021-11-11 Fatima MECHTA-GRIGORIOU Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
BR112022024221A2 (pt) 2020-06-02 2022-12-20 Arcus Biosciences Inc Anticorpos para tigit
WO2021258337A1 (en) * 2020-06-24 2021-12-30 Huahui Health Ltd. Human monoclonal antibodies against tigit for immune related diseases
MX2023000197A (es) 2020-07-07 2023-02-22 BioNTech SE Arn terapeutico para el cancer positivo para vph.
CN111763660A (zh) * 2020-08-07 2020-10-13 南京大学 一种重组溶瘤痘苗病毒及其制备方法和应用
CN115708865A (zh) * 2020-08-25 2023-02-24 沣潮医药科技（上海）有限公司 Tigit免疫粘附素在制备调节血管生成产品中的应用
MX2023004808A (es) * 2020-10-26 2023-05-10 Akeso Biopharma Inc Anticuerpo anti-tigit y composicion farmaceutica y uso del mismo.
AU2021376218A1 (en) 2020-11-08 2023-06-15 Seagen Inc. Combination Therapy
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
TW202222345A (zh) * 2020-11-26 2022-06-16 大陸商信達生物製藥（蘇州）有限公司 包含抗ｔｉｇｉｔ／ｐｄ－１雙特異性抗體的製劑及其製備方法和用途
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022148781A1 (en) 2021-01-05 2022-07-14 Institut Curie Combination of mcoln activators and immune checkpoint inhibitors
KR20230165911A (ko) 2021-04-09 2023-12-05 씨젠 인크. 항-tigit 항체를 사용한 암의 치료 방법
WO2022214652A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
IL307419A (en) 2021-04-09 2023-12-01 Ose Immunotherapeutics A new scaffold for bifunctional molecules with improved properties
CN115925967A (zh) 2021-04-22 2023-04-07 广东菲鹏制药股份有限公司 双特异性多功能融合多肽
TW202304965A (zh) 2021-05-04 2023-02-01 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法
EP4339208A1 (en) * 2021-05-10 2024-03-20 MediMabbio Inc. Anti-tigit antibodies and use thereof
EP4370552A1 (en) 2021-07-13 2024-05-22 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
KR20240038043A (ko) * 2021-07-23 2024-03-22 아케소 바이오파마, 인크. 약학적 조성물 및 용도
CN115838424A (zh) * 2021-09-22 2023-03-24 上海康岱生物医药技术股份有限公司 靶向tigit的单克隆抗体
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
CN116284390A (zh) * 2021-12-21 2023-06-23 广东安普泽生物医药股份有限公司 人tigit抗体及其应用
WO2023149977A1 (en) * 2022-02-04 2023-08-10 Mereo Biopharma 5, Inc. Methods for treating cancer
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
TW202409083A (zh) 2022-05-02 2024-03-01 美商阿克思生物科學有限公司 抗-tigit抗體及其用途
WO2023234748A1 (ko) * 2022-06-03 2023-12-07 메디맵바이오 주식회사 항-tigit 항체 및 이의 용도
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050809A1 (en) 1999-09-28 2008-02-28 Alejandro Abuin Novel human kinases and polynucleotides encoding the same
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
CU23007A1 (es) 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
US20040185040A1 (en) 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
CA2476518A1 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
EP1539228B1 (en) 2002-09-11 2010-12-29 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
WO2006124667A2 (en) 2005-05-12 2006-11-23 Zymogenetics, Inc. Compositions and methods for modulating immune responses
AU2006308847C1 (en) 2005-10-31 2012-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
ES2557953T3 (es) 2006-09-29 2016-01-29 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para diagnosticar y tratar cáncer
US20090258013A1 (en) 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
US8551715B2 (en) 2010-02-12 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
RU2597288C2 (ru) * 2011-02-23 2016-09-10 Ф. Хоффманн-Ля Рош Аг Антитела против человеческого il33r и их применение
ES2715673T3 (es) 2012-12-03 2019-06-05 Bristol Myers Squibb Co Mejora de la actividad anticancerosa de proteínas de fusión FC inmunomoduladoras
JP2016502554A (ja) 2012-12-04 2016-01-28 オンコメッド ファーマシューティカルズ インコーポレイテッド 結合物質を用いた免疫療法
CN103073644B (zh) 2012-12-31 2014-03-12 中国科学技术大学 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用
US9062104B2 (en) 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
ES2819209T3 (es) * 2013-07-16 2021-04-15 Hoffmann La Roche Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 e inhibidores de TIGIT
EP3116542A2 (en) 2014-03-12 2017-01-18 Yeda Research and Development Co., Ltd. Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
WO2015143343A2 (en) 2014-03-21 2015-09-24 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
PE20170140A1 (es) 2014-07-16 2017-03-30 Genentech Inc Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
CR20170060A (es) 2014-08-19 2017-04-18 Merck Sharp & Dohme Anticuerpos anti tigit
RU2718914C2 (ru) 2014-09-13 2020-04-15 Новартис Аг Сочетанные способы лечения с использованием ингибиторов alk
ES2774448T3 (es) 2014-10-03 2020-07-21 Novartis Ag Terapias de combinación
RU2017119428A (ru) 2014-11-06 2018-12-06 Дженентек, Инк. Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
CA2971732A1 (en) * 2014-12-23 2016-06-30 Bristol-Myers Squibb Company Antibodies to tigit
CN107208138A (zh) 2014-12-30 2017-09-26 豪夫迈·罗氏有限公司 用于癌症预后和治疗的方法和组合物
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
AU2016307845B2 (en) 2015-08-14 2020-10-15 Merck Sharp & Dohme Llc Anti-TIGIT antibodies
CN108137691B (zh) 2015-09-02 2021-10-19 耶路撒冷希伯来大学伊萨姆研究发展有限公司 特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体
WO2017048824A1 (en) 2015-09-14 2017-03-23 Compass Therapeutics Llc COMPOSITIONS AND METHODS FOR TREATING CANCER VIA ANTAGONISM OF THE CD155/TIGIT PATHWAY AND TGF-β
MX2018003633A (es) 2015-09-25 2018-08-01 Genentech Inc Anticuerpos anti-tigit y metodos de uso.
AR109625A1 (es) 2015-10-01 2019-01-09 Potenza Therapeutics Inc Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas
MY191649A (en) 2016-03-04 2022-07-05 Jn Biosciences Llc Antibodies to tigit
WO2018102536A1 (en) 2016-11-30 2018-06-07 Oncomed Pharmaceuticals, Inc. Methods for treatment of cancer comprising tigit-binding agents

Also Published As

Publication number Publication date
WO2016191643A4 (en) 2017-03-23
CO2017012342A2 (es) 2018-02-28
JP7203446B2 (ja) 2023-01-13
MD3303379T2 (ro) 2022-02-28
EP3303379A4 (en) 2019-04-17
US10112997B2 (en) 2018-10-30
MX2017014955A (es) 2018-04-13
MA42622A (fr) 2018-06-20
DK3303379T3 (da) 2021-12-06
SI3303379T1 (sl) 2022-01-31
AU2016267577B2 (en) 2020-12-10
HRP20211948T1 (hr) 2022-03-18
JP2018521634A (ja) 2018-08-09
RS62815B1 (sr) 2022-02-28
PT3303379T (pt) 2022-01-06
WO2016191643A2 (en) 2016-12-01
EP3303379A2 (en) 2018-04-11
TW201718646A (zh) 2017-06-01
IL255577B (en) 2022-02-01
TWI715587B (zh) 2021-01-11
ECSP17083779A (es) 2018-02-28
KR20180014050A (ko) 2018-02-07
JP2021118719A (ja) 2021-08-12
PL3303379T3 (pl) 2022-02-07
CN109071620A (zh) 2018-12-21
BR112017025529A2 (pt) 2018-08-07
CY1125260T1 (el) 2023-03-24
EP4011907A1 (en) 2022-06-15
EP3303379B1 (en) 2021-10-13
CN109071620B (zh) 2022-05-10
US10544219B2 (en) 2020-01-28
NZ738008A (en) 2019-08-30
JP6875295B2 (ja) 2021-05-19
AU2016267577A1 (en) 2017-12-21
ES2902150T3 (es) 2022-03-25
SA517390370B1 (ar) 2021-09-12
WO2016191643A3 (en) 2017-01-12
CL2017003021A1 (es) 2018-06-01
CA2987607A1 (en) 2016-12-01
CN115429877A (zh) 2022-12-06
US20190077864A1 (en) 2019-03-14
LT3303379T (lt) 2021-12-10
MA42622B1 (fr) 2021-11-30
IL255577A (en) 2018-01-31
US20160376365A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
HK1243741A1 (zh) 腫瘤壞死因子受體超家族(tnfrsf)結合劑
IL255577B (en) Binding materials - tigit and their uses
HK1231471A1 (zh) -雜芳氧基-和 芳氧基-喹啉- -甲酰胺及其用途
IL264813B (en) 2-oxo-imidazopyridines and their use
SG11201706029VA (en) Anti-senescence compounds and uses thereof
HK1246780A1 (zh) 氮雜-吡啶酮化合物及其用途
ZA201705456B (en) Benzoxaborole compounds and uses thereof
GB201504763D0 (en) Compounds and uses
GB201616439D0 (en) Compounds and uses
HK1247122A1 (zh) 組合及其用途
IL254241A0 (en) Etv2 and its uses
IL264473A (en) GPR156 variants and their uses
HK1250915A1 (zh) 組合物和其用途
SG11201701717UA (en) Antiviral agents and uses thereof
IL253459B (en) Isoergoline compounds and their uses
GB201718875D0 (en) Autophagy-inhibiting compounds and uses thereof
GB2545167B (en) Cloches and use thereof
GB2543375B (en) Compounds and their uses
GB201512216D0 (en) Agents uses and methods
GB201514770D0 (en) Compounds and their use
GB201510548D0 (en) Anti-microbial agents and uses therefor
GB201500278D0 (en) Novel combination and use